{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:40Z","timestamp":1793885740939,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.06.037","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:29:57Z","timestamp":1782401397000},"page":"1453.e1-1453.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with\/without Idarubicin Followed by Second Allogeneic Stem Cell Transplant in the Treatment of Relapsed\/Refractory Acute Myeloid Leukemia\/Myelodysplastic Syndrome Following First Allogeneic Stem Cell Transplant"],"prefix":"10.1016","volume":"32","author":[{"given":"Jacqueline","family":"Hsieh-Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4284-8248","authenticated-orcid":false,"given":"Brian","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tuscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Hoeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.06.037_bib0001","unstructured":"Dotson JL, Lebowitz Y, Myelodysplastic Snydrome. StatPearls. 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534126\/"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.037_bib0002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bjh.16355","article-title":"The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience","volume":"188","author":"Loke","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.037_bib0003","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/j.bbmt.2019.01.016","article-title":"Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zeiser","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.037_bib0004","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.clml.2017.06.002","article-title":"FLAG-Ida regimen as bridge therapy to allotransplantation in refractory\/relapsed acute myeloid leukemia patients","volume":"17","author":"Delia","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.037_bib0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/bmt.2014.300","article-title":"Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after allo-SCT","volume":"50","author":"Sauer","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.037_bib0006","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.037_bib0007","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbmt.2015.07.037","article-title":"Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies","volume":"22","author":"Guieze","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.037_bib0008","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/imj.13522","article-title":"Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse","volume":"48","author":"Lim","year":"2018","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.037_bib0009","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1046\/j.1365-2141.2001.03150.x","article-title":"Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG \u00b1 Ida) and second allogeneic stem cell transplant","volume":"115","author":"Pawson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.06.037_bib0010","unstructured":"AML Response Criteria. CIBMTR. The Medical College of Wisconsin and NMDP. Updated January 27, 2005. Accessed August 23, 2026. http:\/\/www.manula.com\/manuals\/cibmtr\/fim\/1\/en\/topic\/aml-response-criteria"},{"key":"10.1016\/j.jtct.2026.06.037_bib0011","unstructured":"Q9-33: Graft vs Host Disease. CIBMTR. The Medical College of Wisconsin and NMDP. Updated February 11, 2026. Accessed August 23, 2026. http:\/\/manula.com\/manuals\/cibmtr\/fim\/1\/en\/topic\/q15-18-graft-versus-host-disease-allogeneic-only"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.037_bib0012","first-page":"1842","article-title":"FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of \u2018poor risk\u2019 acute myeloid leukemias","volume":"8","author":"Visani","year":"1994","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.037_bib0013","first-page":"513","article-title":"High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia","volume":"81","author":"Clavio","year":"1996","journal-title":"Haematologica"},{"issue":"3-4","key":"10.1016\/j.jtct.2026.06.037_bib0014","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/10428190109057928","article-title":"Treatment of \"poor risk\" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study","volume":"40","author":"Carella","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.037_bib0015","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3346\/jkms.2009.24.3.498","article-title":"The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia","volume":"24","author":"Lee","year":"2009","journal-title":"J Korean Med Sci"},{"issue":"31","key":"10.1016\/j.jtct.2026.06.037_bib0016","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.037_bib0017","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.037_bib0018","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/j.clml.2021.02.007","article-title":"Retrospective analysis of adult patients with relapsed\/refractory acute myeloid leukemia treated with FLAG at a comprehensive cancer center","volume":"21","author":"Tenold","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.037_bib0019","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00277-005-1090-9","article-title":"FLAG-IDA in the treatment of refractory\/relapsed adult acute lymphoblastic leukemia","volume":"84","author":"Specchia","year":"2005","journal-title":"Ann Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:19:23Z","timestamp":1793884763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726005117"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.037","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with\/without Idarubicin Followed by Second Allogeneic Stem Cell Transplant in the Treatment of Relapsed\/Refractory Acute Myeloid Leukemia\/Myelodysplastic Syndrome Following First Allogeneic Stem Cell Transplant","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}